Expand CSTL Menu
CSTL MENU

CSTL Latest Press Releases

-- May 3, 2024 --

DecisionDx-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck Business Wire 7:00 AM

-- May 2, 2024 --

Castle Biosciences Reports First Quarter 2024 Results Business Wire 4:05 PM

-- April 30, 2024 --

Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma Business Wire 4:30 PM

-- April 11, 2024 --

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024 Business Wire 7:00 AM

-- April 10, 2024 --

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations Business Wire 5:00 PM
Castle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year Business Wire 7:00 AM

-- April 4, 2024 --

Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer Business Wire 4:30 PM

-- April 2, 2024 --

Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference Business Wire 7:00 AM

-- March 27, 2024 --

Castle Biosciences Announces Updates to its Board of Directors Business Wire 5:00 PM

-- March 25, 2024 --

Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year Business Wire 7:00 AM

-- March 22, 2024 --

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB Business Wire 4:30 PM

-- March 19, 2024 --

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy Business Wire 7:00 AM

-- March 15, 2024 --

New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older Business Wire 4:30 PM

-- March 12, 2024 --

Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum Business Wire 7:00 AM

-- March 8, 2024 --

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting Business Wire 4:30 PM

-- March 7, 2024 --

In Novel Cohort, New Data Confirms DecisionDx-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups Business Wire 7:00 AM

-- February 28, 2024 --

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results Business Wire 4:05 PM

-- February 26, 2024 --

Study Finds DecisionDx-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging Business Wire 7:00 AM

-- February 7, 2024 --

Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024 Business Wire 7:00 AM

-- January 18, 2024 --

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences' DecisionDx-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma Business Wire 7:00 AM

-- January 14, 2024 --

Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii Business Wire 4:30 AM

-- January 9, 2024 --

Castle Biosciences' Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report Business Wire 7:00 AM

-- January 7, 2024 --

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results Business Wire 8:00 PM

-- December 20, 2023 --

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 7:00 AM